CERS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:00):
Our systems believe the stock currently is overvalued by -0.28% compare to its pairs and should correct downwards.

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety...

Stats
Today's Volume	588 640
Average Volume	935 374
Market Cap	318.01M
EPS	$-0.0532 ( Q1 \| 2024-05-02 )
Next earnings date	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.12 (Sector) 42.63 (Industry) 0
ATR14	$0.00600 (0.35%)

AEMD -9.77%

AFIB -12.68%

AHCO -2.70%

AHPI 0.00%

ALGN -1.16%

ANIK 2.05%

APEN 0.00%

APYX -2.99%

ARAY -3.30%

ATEC -4.50%

AXDX 0.00%

AXGN 6.49%

AXNX 0.10%

AZYO 2.05%

BBLG -2.44%

BIOL 7.80%

BJDX 0.87%

BMRA 0.07%

BRKR -2.32%

BSGM -0.06%

BWAY -3.46%

CERS -2.27%

CFMS 0.44%

CLPT -1.11%

CODX 0.80%

CSII 0.15%

CTKB 0.54%

CTSO -0.43%

CUTR -0.66%

CVRX -2.34%

DCTH -1.31%

DXCM -1.07%

DYNT -16.23%

EAR -4.10%

ECOR 0.00%

EDAP -4.04%

ESTA -4.62%

FONR 0.88%

HJLI -1.98%

HSDT -1.15%

HSKA 0.00%

HYPR 8.07%

IART -0.58%

ICAD -2.69%

ICCM -0.68%

IINN -11.59%

INGN -3.69%

INMD -2.03%

IRIX -3.24%

IRMD -1.14%

IRTC -1.11%

ISO 0.00%

ITMR 0.00%

KIDS -1.91%

LHDX 0.00%

LIVN -0.62%

LNSR -1.22%

LUCD -3.78%

LUNG -1.58%

MASS -7.38%

MDGS 10.28%

MOTS -16.81%

MOVE 5.78%

MSON 0.00%

NAOV -0.10%

NARI 4.24%

NMRD 33.33%

NNOX -2.59%

NPCE -3.17%

NTUS 0.00%

NURO -1.62%

NUVA -2.24%

NUWE -3.18%

NVCN 0.00%

NVNO -2.48%

OBLN -5.86%

OFIX -2.87%

OM -4.16%

PACB -12.41%

PAVM -6.26%

PETV -23.08%

PODD -2.79%

PRCT 1.28%

PROF 2.01%

QIPT -1.24%

QTRX -4.01%

RCEL -2.53%

RPID 3.05%

RSLS 3.86%

RWLK 6.07%

RXST -5.60%

SGHT -5.40%

SIBN -0.23%

SIEN -18.69%

SILK -0.33%

SINT -5.21%

SOLY 0.00%

SRDX -0.33%

SRGA 0.00%

SRTS -6.47%

SWAV 0.00%

TBIO 5.75%

TCMD -4.44%

TELA -4.47%

THMO -16.67%

TIVC -1.19%

TLIS -4.20%

TMCI -2.41%

TMDI 0.00%

TMDX -0.29%

TNDM -2.08%

TNON 18.05%

UFPT 9.56%

VERO -8.17%

VIVE 0.00%

VMD -2.29%

VRAY 0.00%

VREX -2.99%

VVOS 6.31%

XAIR 18.39%

XENT 0.00%

ZIMV -0.66%

Insider Trading

Date	Person	Action	Amount	type
2024-06-05	Witney Frank	Buy	40 000	Common Stock
2024-06-05	Swisher Daniel N Jr	Buy	40 000	Common Stock
2024-06-05	Shan Hua	Buy	40 000	Common Stock
2024-06-05	Schulze Gail	Buy	40 000	Common Stock
2024-06-05	Nachtsheim Jami K	Buy	40 000	Common Stock

INSIDER POWER
51.15
Last 100 transactions
Buy: 2 789 373 \| Sell: 1 097 875

Correlation (AI algo v.1.1b): Overvalued: -0.28% $1.725 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.29 (neutral)

Short: -0.74 (moderate negative)

Signal:(52.153) Neutral

Cerus Corp Correlation

10 Most Positive Correlations
OZEM	1
PAL	0.815
BKHAU	0.809
MDB	0.802

10 Most Negative Correlations
RFAIU	-0.968
BKHA	-0.902
SCLX	-0.85
CTCX	-0.849
LSTA	-0.841
ARBFX	-0.823
OCTO	-0.816
ARM	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cerus Corp Correlation - Currency/Commodity

0.00
( neutral )

0.62
( weak )

0.00
( neutral )

-0.14
( neutral )

Cerus Corp Financials

Annual	2023
Revenue:	$156.37M
Gross Profit:	$84.00M (53.72 %)
EPS:	$-0.210

FY	2023
Revenue:	$156.37M
Gross Profit:	$84.00M (53.72 %)
EPS:	$-0.210

FY	2022
Revenue:	$162.05M
Gross Profit:	$87.09M (53.75 %)
EPS:	$-0.240

FY	2021
Revenue:	$159.52M
Gross Profit:	$96.04M (60.21 %)
EPS:	$-0.316

Financial Reports:

No articles found.

Cerus Corp Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.